Please assess the completion status of the following clinical trial:

Trial Title: Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced (metastatic) RCC~* Histology: clear cell, papillary or chromophobe~* 3 out 6 risk factors (by Memorial Sloan Kettering Cancer Center criteria and one additional criterion: multiple sites of metastasis) or not candidates for or refuse sunitinib.~* Must have at least one measurable metastatic site according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria that has not been previously irradiated.~* Must be deemed surgical candidates for cytoreductive nephrectomy by the urologist.~* Age 18 years of age or older~* Eastern Cooperative Oncology Group (EGOG) PS 0-2~* Adequate bone marrow function~* Adequate liver function as shown by:~* Adequate renal function~* Fasting serum cholesterol AND fasting triglycerides within normal limits~* Signed informed consent~Exclusion Criteria:~* Collecting duct, medullary histologies or sarcomatoid differentiation.~* Central Nervous System (CNS) or leptomeningeal metastases.~* Inappropriate candidates for cytoreductive nephrectomy or who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study~* severely impaired lung function~* uncontrolled diabetes~* active (acute or chronic) or uncontrolled severe infections~* liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis~* Ineligible for cytoreductive nephrectomy~* Current or prior systemic anticancer therapies (including chemotherapy, antibody based therapy, or investigational drugs)~* Other malignancies within the past 3 years except for localized carcinoma of the cervix, basal or squamous cell carcinomas of the skin, or localized prostate cancer with Gleason Score less than 7 treated with radiation or surgery and no evidence of progression.~* Major surgery (defined as requiring general anesthesia) or significant traumatic injury within 4 weeks of start of enrollment~* Anticipated major surgery (other than CN) during the course of the study~* A known history of HIV seropositivity~* Hepatitis C seropositivity~* Chronic, systemic treatment with corticosteroids or another immunosuppressive agent. Topical or inhaled corticosteroids are allowed.~* Immunization with attenuated live vaccines within one week of study entry or during study period~* Known hypersensitivity to RAD001 (everolimus) or other rapamycins or to its excipients~* Impairment of gastrointestinal function or gastrointestinal disease~* Active, bleeding diathesis~* Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods.~* History of noncompliance to medical regimens~* Unwilling to or unable to comply with the protocol including mandated biopsies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): All subjects will take everolimus

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues